Annual Current Liabilities
$1.54 B
+$603.50 M+64.67%
31 December 2023
Summary:
Jazz Pharmaceuticals annual total current liabilities is currently $1.54 billion, with the most recent change of +$603.50 million (+64.67%) on 31 December 2023. During the last 3 years, it has risen by +$727.39 million (+89.88%). JAZZ annual current liabilities is now at all-time high.JAZZ Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Current Liabilities
$1.03 B
-$526.05 M-33.81%
30 September 2024
Summary:
Jazz Pharmaceuticals quarterly total current liabilities is currently $1.03 billion, with the most recent change of -$526.05 million (-33.81%) on 30 September 2024. Over the past year, it has dropped by -$506.71 million (-32.97%). JAZZ quarterly current liabilities is now -34.54% below its all-time high of $1.57 billion, reached on 30 September 2023.JAZZ Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Current Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -33.0% |
| 3 y3 years | +89.9% | +27.3% |
| 5 y5 years | +321.6% | +182.6% |
JAZZ Current Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +89.9% | -34.5% | +46.0% |
| 5 y | 5 years | at high | +321.6% | -34.5% | +182.6% |
| alltime | all time | at high | +6485.1% | -34.5% | +4803.5% |
Jazz Pharmaceuticals Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.03 B(-33.8%) |
| June 2024 | - | $1.56 B(-0.4%) |
| Mar 2024 | - | $1.56 B(+1.7%) |
| Dec 2023 | $1.54 B(+64.7%) | $1.54 B(-2.3%) |
| Sept 2023 | - | $1.57 B(+66.4%) |
| June 2023 | - | $945.26 M(+4.0%) |
| Mar 2023 | - | $908.90 M(-2.6%) |
| Dec 2022 | $933.19 M(+15.3%) | $933.19 M(+14.8%) |
| Sept 2022 | - | $812.95 M(+15.2%) |
| June 2022 | - | $705.44 M(-4.3%) |
| Mar 2022 | - | $737.41 M(-8.9%) |
| Dec 2021 | $809.30 M(+23.8%) | $809.30 M(+10.1%) |
| Sept 2021 | - | $735.05 M(-16.5%) |
| June 2021 | - | $880.59 M(+17.1%) |
| Mar 2021 | - | $752.09 M(+15.0%) |
| Dec 2020 | $653.75 M(+79.4%) | $653.75 M(+1.8%) |
| Sept 2020 | - | $642.13 M(+56.6%) |
| June 2020 | - | $409.96 M(+3.5%) |
| Mar 2020 | - | $396.12 M(+8.7%) |
| Dec 2019 | $364.49 M(+5.5%) | $364.49 M(-6.6%) |
| Sept 2019 | - | $390.44 M(+5.7%) |
| June 2019 | - | $369.49 M(-10.8%) |
| Mar 2019 | - | $414.00 M(+19.8%) |
| Dec 2018 | $345.49 M(+17.5%) | $345.49 M(+1.2%) |
| Sept 2018 | - | $341.29 M(-1.9%) |
| June 2018 | - | $347.95 M(-7.4%) |
| Mar 2018 | - | $375.62 M(+27.8%) |
| Dec 2017 | $293.95 M(+14.2%) | $293.95 M(+9.6%) |
| Sept 2017 | - | $268.18 M(+7.1%) |
| June 2017 | - | $250.39 M(-36.2%) |
| Mar 2017 | - | $392.77 M(+52.6%) |
| Dec 2016 | $257.41 M(+13.6%) | $257.41 M(+10.5%) |
| Sept 2016 | - | $232.86 M(+2.7%) |
| June 2016 | - | $226.72 M(-43.2%) |
| Mar 2016 | - | $398.83 M(+76.0%) |
| Dec 2015 | $226.64 M | $226.64 M(-33.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2015 | - | $340.19 M(+51.1%) |
| June 2015 | - | $225.16 M(+2.1%) |
| Mar 2015 | - | $220.58 M(+1.7%) |
| Dec 2014 | $216.80 M(+6.3%) | $216.80 M(-3.1%) |
| Sept 2014 | - | $223.74 M(+13.1%) |
| June 2014 | - | $197.77 M(-16.9%) |
| Mar 2014 | - | $238.01 M(+16.7%) |
| Dec 2013 | $204.03 M(+6.5%) | $204.03 M(+0.3%) |
| Sept 2013 | - | $203.36 M(+10.3%) |
| June 2013 | - | $184.35 M(-24.4%) |
| Mar 2013 | - | $243.72 M(+27.2%) |
| Dec 2012 | $191.54 M(+262.3%) | $191.54 M(+7.3%) |
| Sept 2012 | - | $178.57 M(-7.1%) |
| June 2012 | - | $192.32 M(+83.9%) |
| Mar 2012 | - | $104.58 M(+97.8%) |
| Dec 2011 | $52.87 M(-11.8%) | $52.87 M(-8.1%) |
| Sept 2011 | - | $57.53 M(-29.2%) |
| June 2011 | - | $81.32 M(+32.3%) |
| Mar 2011 | - | $61.44 M(+2.5%) |
| Dec 2010 | $59.94 M(+1.2%) | $59.94 M(+6.5%) |
| June 2010 | - | $56.28 M(-19.5%) |
| Mar 2010 | - | $69.91 M(+18.0%) |
| Dec 2009 | $59.24 M(-65.9%) | $59.24 M(+55.4%) |
| Sept 2009 | - | $38.11 M(-24.1%) |
| June 2009 | - | $50.21 M(-70.2%) |
| Mar 2009 | - | $168.53 M(-2.9%) |
| Dec 2008 | $173.49 M(+370.7%) | $173.49 M(+161.1%) |
| Sept 2008 | - | $66.44 M(-5.5%) |
| June 2008 | - | $70.30 M(-5.9%) |
| Mar 2008 | - | $74.72 M(+102.7%) |
| Dec 2007 | $36.86 M(+20.8%) | $36.86 M(+17.5%) |
| Sept 2007 | - | $31.36 M(-0.8%) |
| June 2007 | - | $31.63 M(+50.6%) |
| Mar 2007 | - | $21.00 M(-31.2%) |
| Dec 2006 | $30.52 M(+30.8%) | $30.52 M(+30.8%) |
| Dec 2005 | $23.34 M | $23.34 M |
FAQ
- What is Jazz Pharmaceuticals annual total current liabilities?
- What is the all time high annual current liabilities for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly current liabilities year-on-year change?
What is Jazz Pharmaceuticals annual total current liabilities?
The current annual current liabilities of JAZZ is $1.54 B
What is the all time high annual current liabilities for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual total current liabilities is $1.54 B
What is Jazz Pharmaceuticals quarterly total current liabilities?
The current quarterly current liabilities of JAZZ is $1.03 B
What is the all time high quarterly current liabilities for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly total current liabilities is $1.57 B
What is Jazz Pharmaceuticals quarterly current liabilities year-on-year change?
Over the past year, JAZZ quarterly total current liabilities has changed by -$506.71 M (-32.97%)